JEMPERLI is an immunotherapy designed to work with the body to help fight cancer

JEMPERLI is not chemotherapy or radiation. It is an immunotherapy (IH-myoo-noh-THAYR-uh-pee), which means it is designed to work with the body’s immune system to find and attack cancer cells.

Understanding immunotherapy

Here’s how JEMPERLI is designed to work with the body to help fight cancer:

How JEMPERLI works graphic 1

Hidden cancer cellsCancer cells can hidefrom your immune system. Cells are then able to grow and spread

down-arrow
How JEMPERLI works graphic 2

Exposed cancer cellsJEMPERLI may prevent cancer cells from hidingso your immune system can find and attack them

Treatment with JEMPERLI + carboplatin and paclitaxel (CP)

If you have been newly-diagnosed with endometrial cancer that has spread outside your uterus (advanced) or your cancer has returned, your doctor may determine that JEMPERLI + CP is appropriate for you.

This treatment approach:

Puzzle pieces icon

Combines 2 types of medicine that work in different ways

Shield icon

Uses JEMPERLI, which is designed to work with the body’s immune system to fight cancer cells

Arrow targeting tumor icon

Adds carboplatin and paclitaxel (CP) for the first 6 doses, which may help directly attack your tumor and help reduce its size

Together, JEMPERLI + CP may help attack and shrink your tumor.

Biomarker testing can provide important information about your disease

Biomarkers are molecules found in tissues or fluids of your body that show if a condition, process, or disease is normal or abnormal. During normal cell growth, the mismatch repair (MMR) system corrects mistakes that occur in your genes. In endometrial cancer, MMR and MSI are biomarker tests that can provide important information about your disease.

If the MMR system is working properly, errors are corrected and the genes remain stable. This is also known as:

  • MMRp (mismatch repair proficient)
  • OR

  • MSS (microsatellite stable)

If the MMR system is not working properly, errors build up, making the genes unstable. This is also known as:

  • dMMR (mismatch repair deficient)
  • OR

  • MSI-H (microsatellite instability-high)
Biomarker type infographic
dMMR/MSI-H vs. MMRp/MSS biomarkers infographic

dMMR/MSI-H status may be associated with Lynch syndrome, an inherited condition that increases the risk of developing endometrial cancer.

What do the experts say?

National guidelines recommend MMR/MSI testing if you have endometrial cancer. Ask your doctor for information on biomarker testing.

Bar graph icon

JEMPERLI study results

Want to learn how JEMPERLI may help?

See Study Results

IV bag icon

How is JEMPERLI given?

When starting any treatment, it’s natural to have questions about what you may expect—like how JEMPERLI is given.

Get the Details

Download icon

Resources for you

Knowledge is power. That's why we're committed to providing you with educational resources to help you stay informed along your treatment journey.

Go to Resources

Related FAQs

  • How has JEMPERLI been studied?

    Researchers have conducted clinical trials to study the effectiveness, risks, and side effects associated with JEMPERLI. Trials are ongoing.

  • Is advanced or returned endometrial cancer common?

    About 1 in 4 people with endometrial cancer has cancer that has spread outside the uterus (advanced) or has returned.

  • What is a biomarker?

    A biomarker (BY-oh-MAR-ker) is a molecule found in the tissues or fluids of your body that shows if a condition, process, or disease is normal or abnormal. Endometrial cancer may have a biomarker known as dMMR (mismatch repair deficient). Testing for this biomarker provides important information about your cancer and may help your doctor decide what treatment options, including JEMPERLI, may be right for you.